8072
T. Matsumura et al. / Tetrahedron 57 ,2001) 8067±8074
MeCN±H2O +9:1)] to give 12 +5mg). Fraction B 11 +0.71 g)
was also subjected to a Lobar RP-8 column [MeCN±H2O
+3:17)] and HPLC [CHA, MeCN±H2O +9:1)] to give 13
+6 mg). Fraction B10 +1.38 g) was passed through a Lobar
RP-8 column [MeCN±H2O +3:17)] to give eight fractions
+frs. B10-1±B10-8). Fraction B10-4, fr. B10-5 and B10-7 were
subjected to HPLC [CHA, MeCN±H2O +9:1)]. to give 15
+2 mg), 14 +11 mg) and 11 +610 mg), respectively.
C-1, C-3, C-4, C-6; H-5eq/C-3, C-4, C-6; H-6ax/C-2, C-4,
C-5, C-7; H-6eq/C-2, C-4, C-5, C-7; H3-7/C-1, C-2, C-6;
H2-9/ C-4, C-8, C-10; H3-10/C-4, C-8, C-9.
3.2.6. Rel-,1R,2S,4R,8R)-p-menthane-2,8,9-triol ,6). An
amorphous powder, [a]21D2308 +c0.4, MeOH). Positive
FAB-MS m/z: 377 [2M1H]1, 227.1051 [M1K]1 +Calcd for
C10H20KO3; 227.1050), 171 [M2H2O1H]1, 15
3
1
[M22H2O1H]1 +base), 135[M 23H2O1H]1. H NMR
3.2.1. ,1S,2S,4S,8R)-p-Menthane-2,8,9-triol ,1). An
amorphous powder, [a]21D1148 +c0.2, MeOH).
Positive FAB-MS m/z: 377 [2M1H]1, 211 [M1Na]1,
189.1486 [M1H]1 +base, Calcd for C10H21O3; 189.1490),
+pyridine-d5, 500 MHz) d: Table 1. 13C NMR +pyridine-
d5, 125MHz) d: Table 2.
3.2.7. Rel-,1S,2S,4R,8S)-p-menthane-2,8,9-triol ,7).
Colorless needles +MeOH), mp 130±1338C, [a]21D278
+c0.3, MeOH). Positive FAB-MS m/z: 399 [2M1Na]1,
377 [2M1H]1, 227.1032 [M1K]1 +Calcd for C10H20KO3;
227.1050), 189 [M1H]1, 171 [M2H2O1H]1, 15
171 [M2H2O1H]1, 15
3
2[M2H2O1H]1, 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
HMBC correlations: H-1ax/C-2, C-3, C-5, C-6, C-7; H-3ax/
C-1, C-2, C-4, C-5, C-8; H-3eq/C-1, C-2, C-4, C-5, C-8; H-
4ax/C-2, C-3, C-5, C-6, C-8, C-9, C-10; H-5ax/C-1, C-3, C-4,
C-6, C-8; H-5eq/C-1, C-3, C-4, C-6; H-6ax/C-1, C-2, C-4,
C-5, C-7; H-6eq/C-1, C-2, C-4, C-5, C-7; H3-7/C-1, C-2,
C-6; H2-9/ C-4, C-8, C-10; H3-10/C-4, C-8, C-9.
3
1
[M22H2O1H]1 +base), 135[M 23H2O1H]1. H NMR
+pyridine-d5 500 MHz) d: Table 1. 13C NMR +pyridine-d5,
125MHz) d: Table 2. HMBC correlations: H-2eq/C-3;
H-3ax/C-4, C-8; H-4ax/C-3, C-8, C-10; H-5ax/C-4, C-8;
H-6ax/C-1, C-5, C-7; H-6eq/C-1; H3-7/C-1, C-2, C-6; H2-9/
C-4, C-8, C-10; H3-10/C-4, C-8, C-9.
3.2.2. ,1S,2S,4S,8S)-p-Menthane-2,8,9-triol ,2). An amor-
phous powder, [a]21D188 +c0.2, MeOH). Positive FAB-
MS m/z: 377 [2M1H]1, 211 [M1Na]1, 189.1476 [M1H]1
+base, Calcd for C10H21O3; 189.1490), 171 [M2H2O1H]1,
153 [M22H2O1H]1, 135[M 23H2O1H]1. 1H NMR
+pyridine-d5, 500 MHz) d: Table 1. 13C NMR +pyridine-
d5, 125MHz) d: Table 2.
3.2.8. Rel-,1S,2S,4R,8R)-p-menthane-2,8,9-triol ,8). An
amorphous powder, [a]21D2138 +c0.1, MeOH). Positive
FAB-MS m/z: 399 [2M1Na]1, 377 [2M1H]1, 227.1047
[M1K]1 +Calcd for C10H20KO3; 227.1050), 189 [M1H]1,
171 [M2H2O1H]1, 15 3 [M22H2O1H]1 +base), 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
3.2.3. ,1S,2R,4R,8S)-p-Menthane-2,8,9-triol ,3). Colorless
needles +MeOH), mp 119±1228C, [a]25D2318 +c3.1,
MeOH). Positive FAB-MS m/z: 377 [2M1H]1, 227
[M1K]1, 211 [M1Na]1, 189.1502 [M1H]1 +base, Calcd
for C10H21O3; 189.1490), 171 [M2H2O1H]1, 15
[M22H2O1H]1, 135[M 23H2O1H]1. 1H NMR +pyridine-
d5, 500 MHz) d: Table 1. 13C NMR +pyridine-d5, 125MHz)
d: Table 2. HMBC correlations: H-1eq/C-2, C-3, C-5, C-6,
C-7; H-2ax/C-1, C-3, C-4, C-6, C-7; H-3ax/C-1, C-2, C-4,
C-5, C-8; H-3eq/C-1, C-2, C-4, C-5; H-4ax/C-2, C-3, C-5,
C-6, C-8, C-9, C-10; H-5ax/C-1, C-3, C-4, C-6, C-8; H-5eq/
C-1, C-3, C-4, C-6, C-8; H-6ax/C-1, C-2, C-4, C-5, C-7;
H-6eq/C-1, C-2, C-4, C-5, C-7; H3-7/C-1, C-2, C-6; H2-9/
C-4, C-8, C-10; H3-10/C-4, C-8, C-9.
3.2.9. ,1R,2R,4S)-p-Menthane-1,2,8-triol ,9). Colorless
needles +MeOH), mp 134±1358C, [a]23D2258 +c0.2,
MeOH), [a]21D2478 +c0.1, CHCl3). Positive FAB-MS
m/z: 377 [2M1H]1, 211.1305[M 1Na]1 +Calcd for
3
C10H20NaO3;
211.1310),
189
[M1H]1,
171
[M2H2O1H]1, 15
3
2[M2H2O1H]1 +base), 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
HMBC correlations: H-3ax/C-1, C-2, C-5; H-3eq/C-1, C-2,
C-5; H-5ax/C-3, C-4, C-6; H-6ax/C-4, C-5; H-6eq/C-1, C-2,
C-4, C-5; H3-7/C-1, C-2, C-6; H3-9/ C-4, C-8, C-10; H3-10/
C-4, C-8, C-9.
3.2.10. ,1S,2S,4R,8R)-p-Menthane-1,2,8-triol ,10). An
amorphous powder, [a]24D1258 +c0.2, MeOH). Positive
FAB-MS m/z: 377 [2M1H]1, 211.1323 [M1Na]1 +Calcd
for C10H20NaO; 211.1310), 189 [M1H]1, 171
3.2.4. ,1S,2R,4R,8R)-p-Menthane-2,8,9-triol ,4). Color-
less needles +MeOH), mp 115±1178C, [a]21D2358 +c0.4,
MeOH). Positive FAB-MS m/z: 377 [2M1H]1, 211
[M1Na]1, 189.1493 [M1H]1 +base, Calcd for C10H21O3;
189.1490), 171 [M2H2O1H]1, 15 3 [M22H2O1H]1, 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
[M2H2O1H]1, 15
3
2[M2H2O1H]1 +base), 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
HMBC correlations: H-2eq/C-1, C-3, C-6; H-3ax/C-2, C-4,
C-5, C-8; H-3eq/C-1, C-2, C-4, C-5, C-8; H-4ax/C-2, C-3,
C-5, C-6, C-8, C-9, C-10; H-5ax/C-1, C-4, C-6; H-5eq/C-1,
C-3, C-6, C-8; H-6ax/C-1, C-5, C-7; H-6eq/C-1, C-2, C-5,
C-7; H3-7/C-1, C-2, C-6; H2-9/ C-4, C-8, C-10; H3-10/
C-4, C-8, C-9.
3.2.5. Rel-,1R,2S,4R,8S)-p-menthane-2,8,9-triol ,5).
Colorless needles +MeOH), mp 123±1268C, [a]21D2228
+c0.2, MeOH). Positive FAB-MS m/z: 377 [2M1H]1,
227.1040 [M1K]1 +Calcd for C10H20KO3; 227.1050), 171
[M2H2O1H]1, 15
3
2[M2H2O1H]1 +base), 135
[M23H2O1H]1. 1H NMR +pyridine-d5, 500 MHz) d:
Table 1. 13C NMR +pyridine-d5, 125MHz) d: Table 2.
HMBC correlations: H-1ax/C-2, C-5, C-7; H-3ax/C-4, C-5;
H-3eq/C-2, C-4, C-5; H-4ax/C-3, C-5, C-6, C-8, C-10; H-5ax/
3.2.11. ,1S,2R,4R,8S)-p-Menthane-2,8,9-triol 4-O-b-d-
glucopyranoside
,11).
An
amorphous
powder,
[a]25D2468 +c1.8, MeOH). Positive FAB-MS m/z: 373
[M1Na]1, 351.2048 [M1H]1 +base, Calcd for C16H31O8;